Oil matrix formulation

Abstract

This disclosure comprises an oil matrix formulation comprising cannabichromene (CBC); cannabidiol (CBD); at least one terpene; and optionally tetrahydrocannabinolic acid (THC), the oil matrix formulation being resistant to photo-oxidation, crystallization, and discoloration, and having a viscosity in the range of about 3000 to about 5000 centipoise at room temperature. The oil matrix formulation comprises components isolated and purified at concentrations exceeding about 90%, resulting in a final cannabinoid concentration of about 80 to about 90%.

Description

Technical Field

[0001] Cross-Reference to Related Applications This application claims the benefit of and priority to U.S. Provisional Patent Application No. 63 / 590,487 filed on October 16, 2023, the entire contents of which are incorporated herein by reference.

[0002] The present disclosure generally relates to stable cannabinoid matrices that function as bases for a plurality of flavoring compounds, and more particularly relates to plant-derived cannabinoid matrices that demonstrate resistance to photo-oxidation, crystallization, and discoloration, and have a viscosity in the range of approximately 1000 to 5000 centipoise at room temperature.

Background Art

[0003] Unless otherwise indicated herein, the materials described in this section are not prior art to the claims in this specification, and are not admitted to be prior art by inclusion in this section.

[0004] Cannabinoids refer to substances that interact with cannabinoid receptors in the human body. Cannabinoids and their receptors are part of our body's system to help regulate a variety of normal functions, including pain, cravings, and inflammation. The human body produces its own cannabinoids (called endocannabinoids). Cannabis plants also produce cannabinoids. Cannabis plants have merely existed for 30 million years, but contain millions of biologically active substances.

[0005] Cannabidiol (CBD) is one such substance that is naturally crystalline. Many other minor cannabinoids do not readily form crystals. And most forms of CBD distillates contain limited concentrations of minor cannabinoids. In most hemp vape cartridges, cannabinoids must be diluted and emulsified with undesirable substances for the vape oil to maintain its liquid state. Therefore, it is difficult for vape oils to have high concentrations of cannabinoids, potentially resulting in a loss of some of the medical and therapeutic benefits and effects of cannabinoids. Some tetrahydrocannabinol (THC)-free products may include product options that contain crystallized distillates to produce vape oils with higher concentrations of cannabinoids that can remain in a liquid state and be used in many product categories. Such crystallized distillates are solid at room temperature and must be dissolved to construct blended oil products, possessing a distinctive and unpleasant taste across formulations that strictly limits which flavorings produce a product acceptable to the end consumer, with a net cannabinoid content of approximately 65% ​​as a base product, and producing a distinctive pungent taste even when used in low volumes to introduce broad-spectrum components into THC formulations. Hemp oil-based products may crystallize in vials, may contain D8-THC which is illegal in some markets, and may not present a broad-spectrum product; the closest analog is the D9-THC distillate formulation.

[0006] There is growing interest in fully utilizing the surrounding effects and medical benefits of these cannabinoid extracts. The beneficial effects of this proposed synergistic relationship between major and minor cannabinoids in cannabis extracts have not yet been clearly demonstrated. However, existing evidence clearly suggests that the effects of individual cannabinoids are enhanced when all cannabis components act together. Therefore, it is desirable to utilize the medical and therapeutic effects by increasing the surrounding effects through more stable forms of cannabinoid extracts. [Overview of the project]

[0007] Existing problems related to the above, as well as other problems, are overcome by the oil matrix formulations disclosed herein. One embodiment of the present disclosure is an oil matrix formulation. Such an oil matrix formulation comprises at least one component of a plant of the genus Hemp. In an embodiment, the oil matrix formulation comprises at least one non-psychoactive phytocannabinoid. In an embodiment, the oil matrix formulation comprises at least one non-psychoactive phytocannabinoid and at least one mildly psychoactive phytocannabinoid. In an embodiment, the oil matrix formulation comprises at least one non-psychoactive phytocannabinoid, at least one mildly psychoactive phytocannabinoid, and at least one psychoactive phytocannabinoid.

[0008] In embodiments, the oil matrix formulation comprises cannabichromene (CBC), cannabidiol (CBD), and at least one terpene compound. The oil matrix formulation is resistant to photo-oxidation, crystallization, and discoloration, and has a viscosity in the range of about 3000 to about 5000 centipoise at about 25°C.

[0009] In one embodiment, the oil matrix formulation further comprises mild psychoactive plant-derived cannabinoids such as cannabinol (CBN) and / or cannabigerol (CBG).

[0010] In one embodiment, the oil matrix formulation may optionally contain a psychoactive component, such as tetrahydrocannabinolic acid (THC).

[0011] In one embodiment, the above-mentioned cannabichromene (CBC) component and cannabidiol (CBD) may constitute at least 80 percent (80%) of the matrix formulation in a ratio of approximately 50:50 for the stability of the matrix. In another embodiment, the remaining 20 percent (20%) of the matrix may consist of other cannabinoids and terpenes. In another embodiment, the remaining cannabinoids and terpenes are in a ratio of approximately 50:50 in the matrix formulation for the stability of the matrix.

[0012] In one embodiment, the above oil matrix contains approximately 40% by weight of the cannabichromene (CBC) component, approximately 40% by weight of the cannabidiol (CBD) component, approximately 10% by weight of the cannabigerol (CBG) component, and approximately 10% by weight of the terpene component.

[0013] In a further embodiment, the above oil matrix contains approximately 43% by weight of the cannabichromene (CBC) component, approximately 40% by weight of the cannabidiol (CBD) component, approximately 10% by weight of the cannabigerol (CBG) component, and approximately 7% by weight of the terpene component.

[0014] In this embodiment, the oil matrix contains approximately 40% by weight of the cannabichromene (CBC) component, approximately 40% by weight of the cannabidiol (CBD) component, approximately 5% by weight of the cannabigerol (CBG) component, approximately 5% by weight of the cannabinol (CBN) component, and approximately 10% by weight of the terpene component.

[0015] In one embodiment, the above oil matrix contains approximately 43% by weight of the cannabichromene (CBC) component, approximately 40% by weight of the cannabidiol (CBD) component, approximately 5% by weight of the cannabigerol (CBG) component, approximately 5% by weight of the cannabinol (CBN) component, and approximately 7% by weight of the terpene component.

[0016] In one embodiment, the above oil matrix contains approximately 20% by weight of the cannabichromene (CBC) component, approximately 40% by weight of the cannabidiol (CBD) component, approximately 10% by weight of the cannabigerol (CBG) component, approximately 10% by weight of the terpene component, and approximately 20% by weight of the tetrahydrocannabinolic acid (THC) component.

[0017] In one embodiment, the above oil matrix contains approximately 25% by weight of the cannabichromene (CBC) component, approximately 40% by weight of the cannabidiol (CBD) component, approximately 10% by weight of the cannabigerol (CBG) component, approximately 7% by weight of the terpene component, and approximately 15% by weight of the tetrahydrocannabinolic acid (THC) component.

[0018] In this embodiment, the oil matrix contains approximately 30% by weight of the cannabichromene (CBC) component, approximately 40% by weight of the cannabidiol (CBD) component, approximately 5% by weight of the cannabigerol (CBG) component, approximately 5% by weight of the cannabinol (CBN) component, approximately 10% by weight of the terpene component, and approximately 10% by weight of the tetrahydrocannabinolic acid (THC) component.

[0019] In one embodiment, the above oil matrix contains approximately 35% by weight of the cannabichromene (CBC) component, approximately 40% by weight of the cannabidiol (CBD) component, approximately 5% by weight of the cannabigerol (CBG) component, approximately 5% by weight of the cannabinol (CBN) component, approximately 7% by weight of the terpene component, and approximately 5% by weight of the tetrahydrocannabinolic acid (THC) component.

[0020] In one embodiment, the oil matrix formulation further comprises a flavoring compound.

[0021] Another embodiment of the present disclosure is a method for producing an oil matrix formulation. The method comprises weighing each component of the oil matrix formulation. The oil matrix formulation comprises cannabichromene (CBC), cannabidiol (CBD), and at least one terpene. The method comprises placing the weighed components into a chamber of a mixing apparatus. The method comprises heating the components in the mixing apparatus at a temperature of about 140°F to about 160°F for a period of time sufficient to melt the components. For example, a time sufficient to mix the components is in the range of 0.5 hours to 2.0 hours to form a homogeneous mixture.

[0022] Another embodiment of the present disclosure is an oil matrix formulation. The oil matrix formulation comprises a cannabichromene (CBC) component, a cannabidiol (CBD) component, a cannabigerol (CBG) component, a cannabinol (CBN) component, a terpene component, a tetrahydrocannabinolic acid (THC) component, and a flavoring compound. The above oil matrix formulation is resistant to photo-oxidation, crystallization, and discoloration, and has a viscosity in the range of about 1000 to about 5000 centipoise at about 25°C.

[0023] The above summary is for illustrative purposes only and is not intended to be limiting in any way. In addition to the exemplary aspects, embodiments, and features described above, further aspects, embodiments, and features will become apparent by referring to the drawings and the detailed description below. [Brief explanation of the drawing]

[0024] The above and other features of this disclosure will be more fully apparent from the following description and the attached claims, together with the attached drawings. Understanding that these drawings illustrate only some embodiments of this disclosure and should therefore not be considered limitations on the scope of this disclosure, this disclosure will be described more specifically and in detail through the use of the attached drawings.

[0025] [Figure 1]Figure 1 is a system for producing an oil matrix formulation according to the present disclosure. [Detailed Description for Carrying Out the Invention]

[0026] In the following detailed description, reference is made to the accompanying drawings, which form a part hereof. In the drawings, unless the context dictates otherwise, similar reference numerals typically identify similar components. The exemplary embodiments set forth in the detailed description, drawings, and claims are not intended to be limiting. Other embodiments may be utilized, and other changes may be made, without departing from the spirit or scope of the subject matter presented herein. It will be readily appreciated that the aspects of the present disclosure, as generally described herein and illustrated in the figures, may be arranged, substituted, combined, separated, and designed in a wide variety of different configurations, all of which are explicitly contemplated herein. The oil matrix formulation may comprise a stable matrix of cannabinoids that functions as a base for a plurality of flavoring compounds. The above oil matrix formulation may comprise at least one component from a plant of the genus Cannabis. In embodiments, the above oil matrix formulation comprises at least one non-psychotropic botanical cannabinoid. In embodiments, the above oil matrix formulation comprises at least one non-psychotropic botanical cannabinoid and at least one mildly psychotropic botanical cannabinoid. In embodiments, the above oil matrix formulation comprises at least one non-psychotropic botanical cannabinoid, at least one mildly psychotropic botanical cannabinoid, and at least one psychotropic botanical cannabinoid. Each of the components of the plant of the genus Cannabis is isolated and extracted by methods known in the art.

[0027] The above oil matrix formulation is resistant to photo-oxidation, crystallization, and discoloration, and may have a viscosity in the range of about 1000 to about 5000 centipoise at room temperature (about 25°C). The oil matrix formulation of the present disclosure may have a stable shelf life of more than 60 days.

[0028] Figure 1 is a system for producing an oil matrix formulation, arranged in accordance with at least some of the embodiments described herein. The system 100 may include a scale 5, a mixing device 10, and a heater 30. The mixing device 10 may include a chamber 20 and a mixing device 25.

[0029] The system 100 may further include components 40, 45, 50, 55, and 60. In some embodiments, the system 100 may further include component 65. Each of the components 40, 45, 50, 55, 60, and 65 may be a cannabinoid component. Component 40 may include cannabichromene (CBC), component 45 may include cannabidiol (CBD), component 50 may include cannabigerol (CBG), component 55 may include cannabinol (CBN), component 60 may include at least one terpene, and component 65 may include tetrahydrocannabinol acid (THC).

[0030] The components 40, 45, 50, 55, 60, and 65 may each be weighed on the scale 5 prior to mixing. At 102, the components 40, 45, 50, 55, 60, and 65 may each be placed into the chamber 20 of the mixing device 10. The components 40, 45, 50, 55, 60, and 65 may be placed into the chamber 20 of the mixing device 10 in any order. The chamber 20 may be a flask, a beaker, or another chamber made of a material suitable for handling the temperature, stress, and chemistry for mixing the components 40, 45, 50, 55, 60, and 65.

[0031] Once components 40, 45, 50, 55, 60, and 65 have been added to chamber 20, the mixture may be heated by heater 30 at a temperature of approximately 120°F to approximately 160°F for a period of approximately 5 minutes to approximately 1.0 hour, such that the heating is sufficient to melt components 40, 45, 50, 55, 60, and 65 and to aid in the mixing of the components. In embodiments, the heating time may be as little as 5 minutes for small batches, but may be up to 1 hour for large production batches with a total mass exceeding 1 kg using common laboratory equipment. Further means of heating and mixing these materials may be available to the skilled manufacturer and may be readily used in this situation in a number and means determined. Heater 30 may supply heat to chamber 20 by any acceptable laboratory heating method. The molten components 40, 45, 50, 55, 60, and 65 can be mixed together by the mixing device 25 of the mixing apparatus 10 either before or simultaneously with the heating of components 40, 45, 50, 55, 60, and 65 to form a homogeneous mixture 70. The time for mixing components 40, 45, 50, 55, 60, and 65 may be about 0.5 hours to about 2.0 hours to form a homogeneous mixture. The mixing device 25 may be any experimental mixing device with any mixing means, and the specific mixing method is independent of the oil matrix described above, provided that complete homogenization of the materials is achieved when producing the mixture 70. The mixture 70 may have a specific heat depending on the concentration of components 40, 45, 50, 55, 60, and 65. The mixture 70 may be an oil matrix formulation containing a stable matrix of cannabinoids that can function as a base for multiple flavoring compounds. Mixture 70 may be resistant to photo-oxidation, crystallization, and discoloration.

[0032] The total ratio of crystals to liquid may be at least 50:50, and the liquid components (component 40, CBC, and component 60, terpene) may be preferred in mixture 70. Component 55 (CBN) may not exceed 4.5% in liquid solution within mixture 70. Component 40 (CBC) may not exceed 30% in liquid solution within mixture 70. Component 45 (CBD) may not exceed 45% in liquid solution within mixture 70. In embodiments, the amounts of component 55 (CBN) and component 44 in mixture 70 may be adjusted downward to substitute for component 40 (CBC) in order to produce an acceptable mixture 70.

[0033] In one embodiment, the mixture 70 may contain components 40, 45, and 60 to form a stable matrix. For example, for stability, the mixture 70 may contain at least 80% of components 40 and 45 in a ratio of about 50:50. Such a 50:50 ratio of components 40 and 45 may be slightly adjusted to control the viscosity of the mixture 70. The remaining about 20% of the mixture 70 may be about half component 60 and about half any combination of components 40, 45, 50, 55, and / or 65. In another embodiment, the mixture 70 may contain up to 50% component 60, with the remaining 50% containing components 40 and 45 in a ratio of about 50:50 for stability.

[0034] In one embodiment, the mixture 70 may comprise about 40% by weight of component 40, about 40% of component 45, about 10% of component 50, and about 10% of component 60. In another embodiment, the mixture 70 may comprise about 43% by weight of component 40, about 40% of component 45, about 10% of component 50, and about 7% of component 60. In yet another embodiment, the mixture 70 may comprise about 40% by weight of component 40, about 40% of component 45, about 5% of component 50, about 5% of component 55, and about 10% of component 60. In yet another embodiment, the mixture 70 may comprise about 43% by weight of component 40, about 40% of component 45, about 5% of component 50, about 5% of component 55, and about 7% of component 60.

[0035] In some embodiments, the mixture 70 may also optionally contain tetrahydrocannabinolic acid (THC) 65. In such embodiments, the mixture 70 may comprise, by weight, about 20% of component 40, about 40% of component 45, about 10% of component 50, about 10% of component 60, and about 20% of component 65. In another embodiment, the mixture 70 may comprise, by weight, about 25% of component 40, about 40% of component 45, about 10% of component 50, about 7% of component 60, and about 15% of component 65. In yet another embodiment, the mixture 70 may comprise, by weight, about 30% of component 40, about 40% of component 45, about 5% of component 50, about 5% of component 55, about 10% of component 60, and about 10% of component 65. In another embodiment, the mixture 70 may comprise about 35% by weight of component 40, about 40% of component 45, about 5% of component 50, about 5% of component 55, about 7% of component 60, and about 5% of component 65.

[0036] In 104, a flavoring compound 80 may be added to the mixture 70. While the mixture 70 may be maintained at its melting temperature, the flavoring compound 80 is added and mixed with the mixture 70 to form a flavored mixture 90. The flavoring compound 80 may include, but is not limited to, any natural and / or synthetic flavoring molecules, including plant compounds containing flavonoids and terpenes, artificial compounds, and synthetic versions of natural compounds. Once the flavored mixture 90 is mixed and completely homogenized, it may be cooled to room temperature and become a stabilized, room-temperature storable form. The flavored mixture 90 may have a viscosity of about 3000 to about 5000 centipoise at room temperature (about 25°C), which may be optimal for array filling of full vaporization pods and single-piece flow assemblies.

[0037] Either mixture 70 or flavored mixture 90 may be bottled for later filling, transferred directly to a filling machine for immediate filling, or used for direct manual filling of vaporization pods. Optimal storage conditions for mixture 70 or flavored mixture 90 may consist of any other packaging capable of protecting the oil from air and light exposure and protecting the cannabinoid oil from air and light exposure, such as amber vials with phenolic cones, aluminum bottles pre-treated for handling terpenes, laboratory glassware stored in cabinets.

[0038] The mixture 70 or the flavored mixture 90 may be placed inside a pod, packaged, and protected from deterioration by air and light, resulting in an extended shelf life.

[0039] [Table 1]

[0040] [Table 2]

[0041] In Examples 1-12, all components were isolated and purified to concentrations exceeding approximately 90%, and in some cases, the component concentrations were of a purity of approximately 99% or better, which translates to a final cannabinoid concentration of approximately 80-90% for each example of mixture 70. In mixture 70, the liquid-to-crystal ratio may be variable and can directly affect the viscosity of the oil. Mixture 70 may have a target viscosity of approximately 3000-5000 centipoise, but other viscosity ranges may be used. Once mixed, mixture 70 or flavored mixture 90 may be liquid at room temperature (approximately 25°C), which is ideal for machine-based array filling because the normal leakage rate is directly proportional to the temperature and viscosity at the time of filling.

[0042] The oil matrix according to this disclosure may provide an oil matrix that does not contain D9-THC. The oil matrix according to this disclosure may provide an oil matrix that does not contain a base terpene. The oil matrix according to this disclosure may provide an oil matrix that can be flavored with a wide range of flavoring materials. The oil matrix according to this disclosure may provide an oil matrix having an optimal viscosity for filling and vaporization performance at room temperature. The oil matrix according to this disclosure may provide an oil matrix that may be mildly psychoactive according to a test group. The oil matrix according to this disclosure may provide an oil matrix that can be stored at room temperature for more than 60 days.

[0043] In another embodiment, the oil matrix, such as mixture 70 or flavored mixture 90, may be prepared by any of the components 40, 45, 50, 55, 60, and 65 derived from high-terpene full-spectrum extracts. High-terpene full-spectrum extracts can be derived from extraction methods in that the final product preserves flavonoids, phenolic amides, and sterols while removing plant material. Components 40, 45, 50, 55, 60, and 65 of mixture 70 or flavored mixture 90 may be adjusted to fit the matrix of mixture 70 or flavored mixture 90, thereby achieving stability by balancing the material with the addition of more cannabinoids. In some embodiments, the high-terpene extract (THE) of component 40, 45, 50, 55, or 65 may be used as terpene component 60 in the oil matrix of mixture 70 or flavored mixture 90.

[0044] As new extracts and methods are constantly being developed, it is intended that the oil matrix of mixture 70 or flavored mixture 90 may contain new and novel extracts of components 40, 45, 50, 55, 60, and 65 as components.

[0045] In the initial tests of more than several dozen used to determine the formulations in Tables 1 and 2, the following results were observed: The liquid-to-crystalline component ratios of components 40, 45, 55, 60, and 65 affected the viscosity of the final product, mixture 70 or flavored mixture 90. It was found that different cannabinoids could be substituted for others within the oil matrix of mixture 70 or flavored mixture 90. For example, D9-THC from component 65 was used to replace CBC from component 40. It was also found that the amounts of crystalline components of components 40, 45, 50, 55, 60, and 65 could be variable. The oil matrix of mixture 70 and flavored mixture 90 flowed readily at room temperature. It was also found that CBN from component 55 had a maximum solubility of 5%. Shelf stability tests were performed on the example of oil matrix mixture 70 from Tables 1 and 2, and it was demonstrated that there was no significant color change, no crystallization, and stability persisted at room temperature over a two-month period of testing.

[0046] Flavoring 80 is required for the flavored mixture 90, but the composition and profile of the added flavoring 80 are variable. During the above tests, 10 different flavored mixtures 90 were prepared using different flavorings 80. Consistent physical properties such as color, crystallization resistance, and overall stability were demonstrated in all flavored mixtures 90.

[0047] The oil matrix formulations of this disclosure may be used in inhalation vape cartridges, tinctures, capsules, topical creams, and various other product categories, such as gummies and other edible products permitted by regulation, artificial carbonated water and other liquid consumables, and flammable products including, but not limited to, prerolls, joints, cigarettes, and pouches. The oil matrix formulations of this disclosure may also be used in other consumption methods that may be developed in the future, in which case the oil matrix formulations of this disclosure may be applied to future products.

[0048] Finally, the processes and techniques described herein are not inherently related to any particular apparatus and can be carried out by any suitable combination of components. Furthermore, various types of general-purpose devices can be used in accordance with the techniques described herein. It may also be proven advantageous to construct specialized apparatus for carrying out the methods and processes described herein. This disclosure is described in relation to the examples above, and such examples are intended in all embodiments to be illustrative rather than restrictive.

[0049] The foregoing description is illustrative only. Various alternatives and modifications can be devised by those skilled in the art without departing from this disclosure. Accordingly, this disclosure is intended to encompass all such alternatives, modifications, and variations. Embodiments described with reference to the accompanying drawings are presented solely to demonstrate certain examples of this disclosure. Other elements, processes, methods, and techniques that are not substantially different from those described above and / or in the accompanying claims are also intended to be within the scope of this disclosure.

Claims

1. Cannabichromene (CBC); Cannabidiol (CBD); and An oil matrix formulation comprising at least one terpene, It is resistant to photo-oxidation, crystallization, and discoloration. It has a viscosity in the range of approximately 1000 to 5000 centipoise at room temperature. Oil matrix formulation.

2. The present invention further comprises a cannabinoid selected from cannabigerol (CBG), cannabinol (CBN), and / or any other cannabinoid. The oil matrix formulation according to claim 1.

3. It also contains tetrahydrocannabinolic acid (THC), The oil matrix formulation according to claim 2.

4. The cannabichromene (CBC) and cannabidiol (CBD) constitute at least 80% of the oil matrix formulation in a ratio of approximately 50:

50. The oil matrix formulation according to claim 1.

5. The cannabinoids and terpenes constitute approximately 20% of the oil matrix formulation in a ratio of approximately 50:

50. The oil matrix formulation according to claim 2.

6. The aforementioned components are isolated and purified at a concentration exceeding approximately 90%. The oil matrix formulation according to claim 1.

7. The matrix contains approximately 80-90% of the final cannabinoid concentration. The oil matrix formulation according to claim 1.

8. Of the aforementioned oil matrix, The cannabichromene (CBC) component is approximately 40% by weight; The cannabidiol (CBD) component is approximately 40% by weight; The cannabigerol (CBG) component is approximately 10% by weight; and The aforementioned at least one terpene component is present in an amount of about 10% by weight. The oil matrix formulation according to claim 2.

9. Of the aforementioned oil matrix, The aforementioned cannabichromene (CBC) component is approximately 43% by weight; The cannabidiol (CBD) component is approximately 40% by weight; The cannabigerol (CBG) component is approximately 10% by weight; and The aforementioned at least one terpene component is present in an amount of approximately 7% by weight. The oil matrix formulation according to claim 2.

10. Of the aforementioned oil matrix, The cannabichromene (CBC) component is approximately 40% by weight; The cannabidiol (CBD) component is approximately 40% by weight; The cannabigerol (CBG) component is approximately 5% by weight; The cannabinol (CBN) component is approximately 5% by weight; and The aforementioned at least one terpene component is present in an amount of about 10% by weight. The oil matrix formulation according to claim 2.

11. Of the aforementioned oil matrix, The aforementioned cannabichromene (CBC) component is approximately 43% by weight; The cannabidiol (CBD) component is approximately 40% by weight; The cannabigerol (CBG) component is approximately 5% by weight; The cannabinol (CBN) component is approximately 5% by weight; and The aforementioned at least one terpene component is present in an amount of approximately 7% by weight. The oil matrix formulation according to claim 2.

12. Of the aforementioned oil matrix, The cannabichromene (CBC) component is approximately 20% by weight; The cannabidiol (CBD) component is approximately 40% by weight; The cannabigerol (CBG) component is approximately 10% by weight; The aforementioned at least one terpene component is present in an amount of about 10% by weight; and The tetrahydrocannabinolic acid (THC) component is approximately 20% by weight. The oil matrix formulation according to claim 3.

13. Of the aforementioned oil matrix, The aforementioned cannabichromene (CBC) component is approximately 25% by weight; The cannabidiol (CBD) component is approximately 40% by weight; The cannabigerol (CBG) component is approximately 10% by weight; The aforementioned at least one terpene component is present in an amount of about 7% by weight; and The tetrahydrocannabinolic acid (THC) component is approximately 15% by weight. The oil matrix formulation according to claim 3.

14. Of the aforementioned oil matrix, The aforementioned cannabichromene (CBC) component is approximately 30% by weight; The cannabidiol (CBD) component is approximately 40% by weight; The cannabigerol (CBG) component is approximately 5% by weight; The cannabinol (CBN) component is approximately 5% by weight; The aforementioned at least one terpene component is present in an amount of about 10% by weight; and The tetrahydrocannabinolic acid (THC) component is approximately 10% by weight. The oil matrix formulation according to claim 3.

15. Of the aforementioned oil matrix, The cannabichromene (CBC) component is approximately 35% by weight; The cannabidiol (CBD) component is approximately 40% by weight; The cannabigerol (CBG) component is approximately 5% by weight; The cannabinol (CBN) component is approximately 5% by weight; The aforementioned at least one terpene component is present in an amount of about 7% by weight; and The tetrahydrocannabinolic acid (THC) component is approximately 5% by weight. The oil matrix formulation according to claim 3.

16. Further containing flavoring compounds, The oil matrix formulation according to claim 1.

17. A method for producing an oil matrix formulation: In weighing each component of the oil matrix preparation, the components of the oil matrix preparation include cannabichromene (CBC), cannabidiol (CBD), and at least one terpene; The weighed components mentioned above are placed into the chamber of the mixing apparatus; Heating the aforementioned components in the mixing apparatus at a predetermined temperature for a predetermined period of time sufficient to melt the components; and This includes mixing the molten components to form a uniform oil matrix formulation. method.

18. The oil matrix preparation further comprises cannabigerol (CBG) and / or cannabinol (CBN). A method for producing the oil matrix formulation described in claim 17.

19. The component of the oil matrix formulation further comprises tetrahydrocannabinolic acid (THC). A method for producing the oil matrix formulation described in claim 18.

20. The aforementioned components are isolated and purified at a concentration exceeding approximately 90%. A method for producing the oil matrix formulation described in claim 17.

21. The oil matrix formulation contains a final cannabinoid concentration of approximately 80 to 90%. A method for producing the oil matrix formulation described in claim 17.

22. Of the aforementioned oil matrix, The cannabichromene (CBC) component is approximately 40% by weight; The cannabidiol (CBD) component is approximately 40% by weight; The cannabigerol (CBG) component is approximately 10% by weight; and The aforementioned at least one terpene component is present in an amount of about 10% by weight. A method for producing the oil matrix formulation described in claim 18.

23. Of the aforementioned oil matrix, The cannabichromene (CBC) component is approximately 40% by weight; The cannabidiol (CBD) component is approximately 40% by weight; The cannabigerol (CBG) component is approximately 5% by weight; The cannabinol (CBN) component is approximately 5% by weight; and The aforementioned at least one terpene component is present in an amount of about 10% by weight. A method for producing the oil matrix formulation described in claim 18.

24. Of the aforementioned oil matrix, The cannabichromene (CBC) component is approximately 20% by weight; The cannabidiol (CBD) component is approximately 40% by weight; The cannabigerol (CBG) component is approximately 10% by weight; The aforementioned at least one terpene component is present in an amount of about 10% by weight; and The tetrahydrocannabinolic acid (THC) component is approximately 20% by weight. A method for producing the oil matrix formulation described in claim 19.

25. Cannabichromene (CBC); Cannabidiol (CBD); Cannabigerol (CBG); Cannabinol (CBN); At least one terpene; Tetrahydrocannabinolic acid (THC); and An oil matrix formulation containing a flavoring compound, It is resistant to photo-oxidation, crystallization, and discoloration. It has a viscosity in the range of approximately 3000 to 5000 centipoise at room temperature. Oil matrix formulation.

26. The components of the aforementioned oil matrix formulation are isolated and purified at a concentration exceeding approximately 90%. The oil matrix formulation according to claim 23.

27. The matrix contains approximately 80-90% of the final cannabinoid concentration. The oil matrix formulation according to claim 23.

28. An oil matrix formulation, Cannabichromene (CBC) and cannabidiol (CBD) are contained in approximately 80% of the oil matrix formulation in a ratio of approximately 50:

50. Approximately 20% of the aforementioned oil matrix formulation consists of other cannabinoids and terpenes in a ratio of approximately 50:

50. Oil matrix formulation.

Images